Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment entities : Alkermes plc save search
Insights on the Substance Abuse Treatment Global Market to 2030 - by Treatment and Region
Published: 2023-01-30 (Crawled : 13:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -2.59%
H: 3.12%
C: 1.79%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.74%
H: 0.2%
C: -1.24%
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 0.07%
H: 0.83%
C: -0.86%
treatment global market
Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Published: 2023-01-17 (Crawled : 12:00) - investor.alkermes.com
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 2.31%
H: 2.43%
C: 2.15%
treatment designation melanoma nemvaleukin innovation
New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey
Published: 2022-01-06 (Crawled : 12:30) - investor.alkermes.com
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 0.52%
H: 3.76%
C: 3.29%
treatment order disease
Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders
Published: 2021-11-11 (Crawled : 12:15) - prnewswire.com
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: -1.59%
H: 1.86%
C: -1.05%
treatment neurodegenerative neurological phase 1 phase 2
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer
Published: 2021-10-25 (Crawled : 11:00) - investor.alkermes.com
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 2.22%
H: 2.22%
C: 2.15%
treatment fda fda fast track fast track cancer nemvaleukin ovarian cancer fast track designation designation
Alkermes Announces Commercial Availability of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder
Published: 2021-10-18 (Crawled : 19:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.14%
H: 1.98%
C: 0.43%
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: -4.36%
treatment schizophrenia commercialization
Global Depression Treatment Market (2020 to 2026) - Featuring Allergen, Bausch Health Companies and Lief Therapeutics Among Others
Published: 2021-08-05 (Crawled : 16:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.42%
H: 0.31%
C: 0.13%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -0.09%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.69%
H: 0.37%
C: 0.34%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.14%
H: 0.3%
C: 0.22%
GRMN | $139.52 -0.85% 0.0% 2.9M
|
Electronic Technology
|
| O: 0.44%
H: 0.65%
C: 0.55%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.48%
H: 0.46%
C: 0.43%
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 1.22%
H: 0.39%
C: -1.17%
treatment depression
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Published: 2021-08-02 (Crawled : 12:00) - biospace.com/
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 2.62%
H: 3.09%
C: 2.82%
treatment fda fda fast track fast track nemvaleukin mucosal melanoma fast track designation designation
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
Published: 2021-06-01 (Crawled : 11:00) - investor.alkermes.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.29%
H: 0.28%
C: -0.95%
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 0.79%
H: 1.4%
C: 1.31%
treatment fda schizophrenia fda approval approval
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Published: 2021-03-11 (Crawled : 12:07) - investor.alkermes.com
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 1.56%
H: 1.79%
C: -0.1%
treatment fda drug designation
NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine
Published: 2021-01-14 (Crawled : 12:08) - investor.alkermes.com
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 0.09%
H: 1.08%
C: 0.73%
treatment injection
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder
Published: 2020-10-09 (Crawled : 10:21) - investor.alkermes.com
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
| Email alert
Add to watchlist
fda schizophrenia treatment
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.